0001654954-19-010406.txt : 20190905 0001654954-19-010406.hdr.sgml : 20190905 20190905163448 ACCESSION NUMBER: 0001654954-19-010406 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190829 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20190905 DATE AS OF CHANGE: 20190905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sanara MedTech Inc. CENTRAL INDEX KEY: 0000714256 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 592220004 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-11808 FILM NUMBER: 191077542 BUSINESS ADDRESS: STREET 1: 1200 SUMMIT AVE STREET 2: SUITE 414 CITY: FORT WORTH STATE: TX ZIP: 76102 BUSINESS PHONE: 817-529-2300 MAIL ADDRESS: STREET 1: 1200 SUMMIT AVE STREET 2: SUITE 414 CITY: FORT WORTH STATE: TX ZIP: 76102 FORMER COMPANY: FORMER CONFORMED NAME: WOUND MANAGEMENT TECHNOLOGIES, INC. DATE OF NAME CHANGE: 20080611 FORMER COMPANY: FORMER CONFORMED NAME: MB SOFTWARE CORP DATE OF NAME CHANGE: 19960805 FORMER COMPANY: FORMER CONFORMED NAME: INAV TRAVEL CORPORATION DATE OF NAME CHANGE: 19920703 8-K 1 smti_8k.htm CURRENT REPORT Blueprint
 

UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 29, 2019
 
SANARA MEDTECH INC.
 
(Exact name of registrant as specified in its charter)
 
 Texas
  000-11808
 59-2219994
 (State or other jurisdiction of incorporation)
  (Commission File Number)
 (I.R.S. Employer Identification No.)
 
 
 1200 Summit Avenue, Suite 414 Fort Worth, Texas
 76102
 (Address of principal executive offices)
 (zip code)
 
                                                                                                                
Registrant’s telephone number, including area code: (817)-529-2300
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
☐           
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐           
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐           
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐           
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
Title of each class
Trading Symbol(s)
 
Name of each exchange on which registered
 
 
 
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
 
Emerging growth company ☐
 
 
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

 
 
 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
Effective August 29, 2019, the Board of Directors (the “Board”) of Sanara MedTech Inc. (the “Company”) voted to expand the size of the Board from four to six persons and elected Dr. Kenneth Thorpe and Ms. Ann Beal Salamone to the Company’s Board.
 
Kenneth E. Thorpe, Ph.D., is the Robert W. Woodruff Professor and Chair of the Department of Health Policy & Management in the Rollins School of Public Health of Emory University in Atlanta, Georgia. Dr. Thorpe previously held health policy professorships at Tulane University, the University of North Carolina at Chapel Hill, Harvard University School of Public Health, and Columbia University. Dr. Thorpe was Deputy Assistant Secretary for Health Policy in the U.S. Department of Health and Human Services from 1993 to 1995 during the Clinton Administration.
 
Ann Beal Salamone, M.S. is Co-Founder and Chairman of Rochal Industries, LLC (“Rochal”). She is one of the principal inventors of Rochal’s liquid bandages, antimicrobial compositions and skin regeneration products for burn and wound treatment. She has developed products for electronics, water purification, personal care and healthcare and has invested in and served on the boards for several entrepreneurial companies and has co-founded six companies. Ann is a member of the National Academy of Engineering and The Academy of Medicine, Engineering & Science of Texas (TAMEST).
 
As previously disclosed in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on July 12, 2019, the Company executed a license agreement with Rochal whereby Sanara MedTech Inc. acquired an exclusive world-wide license to market, sell and further develop antimicrobial products for the prevention and treatment of microbes on the human body utilizing certain Rochal patents and pending patent applications. The Company is currently examining the acquisition of additional licenses from Rochal related to skin protectant and wound care products.
 
The Company believes the addition of Dr. Thorpe and Ms.Salamone to its Board represents an important step in the Company’s growth plans. Dr. Thorpe’s deep understanding of healthcare policy and economics and Ms. Salamone's strong background in research/development and commercialization add key expertise in two important areas of the Company's business.
 
 
 
 
SIGNATURE

 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 Sanara MedTech Inc.
 
 
 
 
 
Date: September 5, 2019
By:  
/s/ Michael D. McNeil
 
 
 
Name: Michael D. McNeil  
 
 
 
Title: Chief Financial Officer